Logo image of SURF

SURFACE ONCOLOGY INC (SURF) Stock Fundamental Analysis

NASDAQ:SURF - Nasdaq - US86877M2098 - Common Stock - Currency: USD

1.07  -0.01 (-0.93%)

After market: 1.07 0 (0%)

Fundamental Rating

2

Overall SURF gets a fundamental rating of 2 out of 10. We evaluated SURF against 572 industry peers in the Biotechnology industry. The financial health of SURF is average, but there are quite some concerns on its profitability. SURF is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SURF has reported negative net income.
SURF had a negative operating cash flow in the past year.
In the past 5 years SURF reported 4 times negative net income.
In the past 5 years SURF reported 4 times negative operating cash flow.
SURF Yearly Net Income VS EBIT VS OCF VS FCFSURF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

SURF has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SURF Yearly ROA, ROE, ROICSURF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 100 200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SURF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SURF Yearly Profit, Operating, Gross MarginsSURF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

SURF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SURF has been increased compared to 1 year ago.
SURF has a worse debt/assets ratio than last year.
SURF Yearly Shares OutstandingSURF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
SURF Yearly Total Debt VS Total AssetsSURF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -6.54, we must say that SURF is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SURF (-6.54) is worse than 72.65% of its industry peers.
SURF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.54
ROIC/WACCN/A
WACC9.86%
SURF Yearly LT Debt VS Equity VS FCFSURF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

SURF has a Current Ratio of 3.60. This indicates that SURF is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.60, SURF is doing worse than 64.62% of the companies in the same industry.
A Quick Ratio of 3.60 indicates that SURF has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.60, SURF is doing worse than 64.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6
SURF Yearly Current Assets VS Current LiabilitesSURF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

SURF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.60%.
Looking at the last year, SURF shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
Measured over the past years, SURF shows a quite strong growth in Revenue. The Revenue has been growing by 18.57% on average per year.
EPS 1Y (TTM)-18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3Y24.89%
Revenue growth 5Y18.57%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.56% on average over the next years.
Based on estimates for the next years, SURF will show a very strong growth in Revenue. The Revenue will grow by 21.55% on average per year.
EPS Next Y-41.08%
EPS Next 2Y-21.95%
EPS Next 3Y6.29%
EPS Next 5Y5.56%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-37.88%
Revenue Next 5Y21.55%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SURF Yearly Revenue VS EstimatesSURF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
SURF Yearly EPS VS EstimatesSURF Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SURF. In the last year negative earnings were reported.
Also next year SURF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SURF Price Earnings VS Forward Price EarningsSURF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SURF Per share dataSURF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.95%
EPS Next 3Y6.29%

More info and screens

0

5. Dividend

5.1 Amount

SURF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURFACE ONCOLOGY INC

NASDAQ:SURF (9/7/2023, 8:23:11 PM)

After market: 1.07 0 (0%)

1.07

-0.01 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-02 2023-08-02/bmo
Earnings (Next)10-31 2023-10-31/bmo
Inst Owners1.16%
Inst Owner Change-96.44%
Ins Owners18.04%
Ins Owner Change0%
Market Cap65.08M
Analysts76.36
Price Target2.43 (127.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.65%
Min EPS beat(2)-33.43%
Max EPS beat(2)10.13%
EPS beat(4)2
Avg EPS beat(4)-2.3%
Min EPS beat(4)-33.43%
Max EPS beat(4)18.07%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-54.6%
EPS NQ rev (1m)1.63%
EPS NQ rev (3m)-5.42%
EPS NY rev (1m)-11.28%
EPS NY rev (3m)-9.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z -6.54
F-Score2
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)15.46%
Cap/Depr(5y)56.41%
Cap/Sales(3y)2.05%
Cap/Sales(5y)3.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-41.08%
EPS Next 2Y-21.95%
EPS Next 3Y6.29%
EPS Next 5Y5.56%
Revenue 1Y (TTM)-100%
Revenue growth 3Y24.89%
Revenue growth 5Y18.57%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-37.88%
Revenue Next 5Y21.55%
EBIT growth 1Y-42.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-372.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-371.18%
OCF growth 3YN/A
OCF growth 5YN/A